Radioembolization with holmium-containing microspheres: Use of the Holmium Platform for the treatment of patients with hepatocellular carcinoma
- Conditions
- C22.0Liver cell carcinoma
- Registration Number
- DRKS00032073
- Lead Sponsor
- niversitätsklinikum Jena, Klinik für Nuklearmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Radioembolization treatment using the Holmium Platform (QuiremScout, Q-Suite, QuiremSpheres)
Exclusion Criteria
none
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival (end of follow-up 12 months after enrollment of the final patient)
- Secondary Outcome Measures
Name Time Method progression free survival (liver-related, overall)